ZURNAI
Live / Applied — First extension granted (statement of use) (as of 04 Sept 2025)
What this means for you
Not registered yet, but its 12 Jun 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98597572
- Mark type
- Stylized text
- Filed
- 12 Jun 2024
- Published for opposition
- 21 Jan 2025
- Attorney of record
- Fara S. Sunderji
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Pharmaceuticals, namely, opioid antagonists; Injectors filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Injectors filled with opioid antagonists; Injectable pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Injectable pharmaceuticals, namely, opioid antagonists
Owner
- Purdue Pharma L.P., Stamford, CT, US
- Purdue Pharma L.P., Stamford, CT, US
Prosecution history
- 10 Nov 2025 — TEAS STATEMENT OF USE RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Sept 2025 — SOU EXTENSION 1 GRANTED
- 04 Sept 2025 — SOU EXTENSION 1 FILED
- 04 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 18 Mar 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 21 Jan 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 21 Jan 2025 — PUBLISHED FOR OPPOSITION
- 15 Jan 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 27 Dec 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 18 Dec 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 18 Dec 2024 — NON-FINAL ACTION E-MAILED
- 18 Dec 2024 — NON-FINAL ACTION WRITTEN
- 18 Dec 2024 — ASSIGNED TO EXAMINER
- 12 Jun 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED